Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Total Current Liabilities (2020 - 2023)

Candel Therapeutics' Total Current Liabilities history spans 4 years, with the latest figure at $10.3 million for Q3 2023.

  • For Q3 2023, Total Current Liabilities rose 75.09% year-over-year to $10.3 million; the TTM value through Sep 2023 reached $10.3 million, up 75.09%, while the annual FY2022 figure was $5.6 million, 4.72% up from the prior year.
  • Total Current Liabilities for Q3 2023 was $10.3 million at Candel Therapeutics, up from $8.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $10.3 million in Q3 2023 and bottomed at $4.4 million in Q3 2021.
  • The 4-year median for Total Current Liabilities is $5.5 million (2022), against an average of $6.0 million.
  • The largest YoY upside for Total Current Liabilities was 75.09% in 2023 against a maximum downside of 4.31% in 2023.
  • A 4-year view of Total Current Liabilities shows it stood at $4.7 million in 2020, then increased by 13.77% to $5.4 million in 2021, then increased by 4.72% to $5.6 million in 2022, then skyrocketed by 83.92% to $10.3 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Total Current Liabilities are $10.3 million (Q3 2023), $8.2 million (Q2 2023), and $5.2 million (Q1 2023).